Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease

NACompletedINTERVENTIONAL
Enrollment

940

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

June 30, 2009

Conditions
Percutaneous Coronary Artery InterventionCoronary Artery Bypass GraftAcute Coronary Syndrome
Interventions
DRUG

cipher prescription 1

Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days

DRUG

cipher prescription 2

Placebo include amidon、bitter principles and diluents bases once daily for 180 days

All Listed Sponsors
collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region

UNKNOWN

collaborator

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

OTHER

collaborator

Teaching Hospital of Nanjin University of Traditional Chinese Medicine

UNKNOWN

collaborator

Second People's Hospital, Fujian Province

OTHER

collaborator

Liaoning University of Traditional Chinese Medicine

OTHER

collaborator

Guangzhou Overseas Chinese Hospital

UNKNOWN

collaborator

Beijing Tongren Hospital

OTHER

collaborator

Shanghai 10th People's Hospital

OTHER

collaborator

PLA.The Military General Hospital of Beijing

UNKNOWN

collaborator

The Sixth Affliated Hospital of Jinan University

UNKNOWN

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

Gansu Provincial Hospital

OTHER

collaborator

Shaanxi Provincial People's Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

The Fifth Affliated Hospital of Guangxi Medical University

UNKNOWN

lead

Guangzhou University of Chinese Medicine

OTHER

NCT00965471 - Effect of Chinese Traditional Medicine for Post Revascularization Treatment of Coronary Artery Disease | Biotech Hunter | Biotech Hunter